Holen Sie sich die Stockscreener-App
36.83
1.56%
0.23
Schlusskurs vom Vortag:
$36.60
Offen:
$36.58
24-Stunden-Volumen:
23,565
Relative Volume:
0.01
Marktkapitalisierung:
$5.64B
Einnahmen:
$3.44B
Nettoeinkommen (Verlust:
$-8.30M
KGV:
-247.68
EPS:
-0.1487
Netto-Cashflow:
$43.30M
1W Leistung:
-3.45%
1M Leistung:
-12.40%
6M Leistung:
+15.90%
1J Leistung:
-18.42%
1-Tages-Spanne:
$36.15
$37.20
1-Wochen-Bereich:
$35.98
$39.54
52-Wochen-Spanne:
$28.53
$56.22
Bruker Corp Stock (BRKR) Company Profile
Firmenname
Bruker Corp
Sektor
Branche
Telefon
978663-3660
Adresse
40 MANNING RD, BILLERICA, MA
Compare BRKR vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BRKR
Bruker Corp
|
37.08 | 5.57B | 3.44B | -8.30M | 43.30M | -0.1487 |
|
ABT
Abbott Laboratories
|
109.97 | 192.10B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
355.96 | 137.25B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
89.76 | 115.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.71 | 103.81B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.34 | 49.82B | 6.07B | 1.06B | 1.34B | 1.8063 |
Bruker Corp Stock (BRKR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-12-09 | Eingeleitet | Goldman | Sell |
| 2025-11-20 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-19 | Eingeleitet | Guggenheim | Buy |
| 2024-12-10 | Eingeleitet | UBS | Neutral |
| 2024-12-05 | Hochstufung | Goldman | Sell → Neutral |
| 2024-10-15 | Eingeleitet | Barclays | Overweight |
| 2024-09-30 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-02-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-21 | Eingeleitet | UBS | Buy |
| 2022-08-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-06-15 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2021-02-05 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-12-02 | Eingeleitet | Goldman | Sell |
| 2020-11-16 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-05-01 | Herabstufung | Cleveland Research | Buy → Neutral |
| 2020-04-02 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2020-04-01 | Herabstufung | Needham | Strong Buy → Hold |
| 2020-03-26 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-09-26 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | Hochstufung | Goldman | Sell → Neutral |
| 2019-06-24 | Bestätigt | Needham | Strong Buy |
| 2019-06-21 | Bestätigt | BofA/Merrill | Neutral |
| 2019-05-30 | Eingeleitet | Wolfe Research | Peer Perform |
| 2019-05-06 | Bestätigt | Needham | Strong Buy |
| 2019-05-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-03 | Hochstufung | UBS | Sell → Neutral |
| 2019-04-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2019-02-12 | Bestätigt | BTIG Research | Buy |
| 2019-01-03 | Eingeleitet | Needham | Strong Buy |
Alle ansehen
Bruker Corp Aktie (BRKR) Neueste Nachrichten
Bruker Corporation $BRKR Position Increased by Ceredex Value Advisors LLC - MarketBeat
Is Bruker (BRKR) Quietly Recasting Its Competitive Moat With Spatial Biology And Proteomics Upgrades? - simplywall.st
These analysts cut their forecasts on Bruker following Q4 results - MSN
Citigroup Inc. Sells 29,083 Shares of Bruker Corporation $BRKR - MarketBeat
Bruker Corporation $BRKR Shares Acquired by Rhenman & Partners Asset Management AB - MarketBeat
Bio-Techne, Bruker, DexCom, STERIS, and Teleflex Shares Plummet, What You Need To Know - Finviz
RSI Alert: Bruker (BRKR) Now Oversold - Nasdaq
Research Tools & Consumables Stocks Q4 In Review: Bruker (NASDAQ:BRKR) Vs Peers - Yahoo Finance
Bruker Corp To Go Ex-Dividend On March 23rd, 2026 With 0.05 USD Dividend Per Share - 富途牛牛
BRKRP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BRKR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BofA Securities Maintains Bruker Corp(BRKR.US) With Buy Rating, Maintains Target Price $49 - 富途牛牛
Artisan Partners Limited Partnership Invests $13.69 Million in Bruker Corporation $BRKR - MarketBeat
Bruker Corp. Experiences Revision in Stock Evaluation Amid Market Volatility - Markets Mojo
Assessing Bruker (BRKR) Valuation After New Spatial Biology Platforms And Collaboration Updates - simplywall.st
BRKR PE Ratio & Valuation, Is BRKR Overvalued - Intellectia AI
Beyond the Balance Sheet: What SWOT Reveals About Bruker Corp (B - GuruFocus
Bruker (NASDAQ: BRKR) outlines 2025 business segments, risks and $2.57B backlog - Stock Titan
Bruker (BRKR): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Bruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics With the Launch of CellScape XR - 富途牛牛
Is Bruker (BRKR) Now Offering Value After A Prolonged Share Price Slump? - Yahoo Finance
Bruker Corporation (NASDAQ:BRKR) Given Average Rating of "Hold" by Brokerages - MarketBeat
New Bruker tool targets 3,000-patient tumor study in spatial proteomics - Stock Titan
Is Bruker (BRKR) Now Attractive After A 21% One Year Share Price Decline? - simplywall.st
Reasons Why Bruker Corporation (BRKR) Appears So Attractive - Finviz
Inside Bruker and Noetik’s push toward 1B mapped human cells - Stock Titan
Bruker unveils spatial biology platforms at AGBT conference - Investing.com
Bruker unveils spatial biology platforms at AGBT conference By Investing.com - Investing.com Canada
Bruker Announces Major Advancements at AGBT to Enable Complete High-Fidelity Spatial Biology Across the Biological Spectrum - Yahoo Finance
Bruker Unveils New Spatial Biology Platforms at AGBT 2026 - Intellectia AI
Bruker announces board changes and declares quarterly dividend By Investing.com - Investing.com South Africa
Bruker announces board changes and declares quarterly dividend - Investing.com
Envestnet Asset Management Inc. Sells 43,490 Shares of Bruker Corporation $BRKR - MarketBeat
3D Protein Structure Analysis Market Report 2026 Featuring - GlobeNewswire
3D Protein Structure Analysis Market Report 2026 Featuring Profiles of Merck, Bruker Corp., Thermo Fisher Scientific, JEOL, Spectris and Other Leading Players - Yahoo Finance UK
The Top 5 Analyst Questions From Bruker's Q4 Earnings Call - Finviz
Nasdaq Analyst Becomes Optimistic; Check Out the Top 5 Upgrades for Thursday - Intellectia AI
The Top 5 Analyst Questions From Bruker’s Q4 Earnings Call - Yahoo Finance
Bruker (BRKR) executive exercises options and sells 2,000 shares - Stock Titan
Don't Overlook Bruker (BRKR) International Revenue Trends While Assessing the Stock - Yahoo Finance
Bruker Corp (BRKR) Shares Up 3.12% on Feb 17 - GuruFocus
Institutional Orbis investors report 9.8% Bruker (NASDAQ: BRKR) ownership stake - Stock Titan
Bruker's Q4 Earnings Lag Estimates, Margins Contract, Stock Down - Nasdaq
US$48.43: That's What Analysts Think Bruker Corporation (NASDAQ:BRKR) Is Worth After Its Latest Results - 富途牛牛
Analysts Have Been Trimming Their Bruker Corporation (NASDAQ:BRKR) Price Target After Its Latest Report - simplywall.st
Analysts Conflicted on These Healthcare Names: Crispr Therapeutics AG (CRSP) and Bruker (BRKR) - The Globe and Mail
A Quick Look at Today's Ratings for Bruker Corp(BRKR.US), With a Forecast Between $35 to $49 - 富途牛牛
Can Bruker Corporation expand into new marketsPortfolio Gains Summary & Stepwise Trade Execution Plans - mfd.ru
A Look At Bruker (BRKR) Valuation After Mixed Earnings And Soft 2026 Growth Outlook - Yahoo Finance
Bruker’s 2025 Earnings Call Maps a Cautious Recovery - TipRanks
Forecasting The Future: 15 Analyst Projections For Bruker - Benzinga
Finanzdaten der Bruker Corp-Aktie (BRKR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.23%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):